Method for producing PF1378a, protein, nucleic acid, and transformant

The method of contacting PF1378B with proteins encoded by the g5141 gene or its mutants in microorganism cells addresses the challenge of producing PF1378A by converting precursor compounds, providing a biosynthetic pathway for PF1378A production.

WO2024242102A1PCT designated stage expired Publication Date: 2024-11-28MITSUI CHEM CROP & LIFE SOLUTIONS INC +1

Patent Information

Application Number
PCT/JP2024/018666
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-23
Filing Date
2024-05-21
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

There is no known technique for manufacturing PF1378A using liquid culture, and it is difficult to synthesize chemically, necessitating biosynthesis by microbial culture, requiring elucidation of its biosynthetic pathway for production.

Method used

A method involving contacting PF1378B with proteins encoded by the g5141 or g5151a genes or their mutants to convert PF1378B into PF1378A and PF1378C into PF1378B, within microorganism cells, utilizing specific amino acid and nucleotide sequences for protein and nucleic acid encoding, to produce PF1378A.

Benefits of technology

This method provides a manufacturing technology for producing PF1378A by identifying and utilizing specific proteins and nucleic acids to convert precursor compounds, enabling efficient biosynthesis within microorganism cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-C000001
    Figure JPOXMLDOC01-APPB-C000001
  • Figure JPOXMLDOC01-APPB-C000002
    Figure JPOXMLDOC01-APPB-C000002
  • Figure JPOXMLDOC01-APPB-C000003
    Figure JPOXMLDOC01-APPB-C000003
Patent Text Reader

Abstract

This method for producing PF1378A comprises a step for bringing PF1378B into contact with one or more proteins to obtain PF1378A, the one or more proteins selected from the group consisting of: (1) a protein comprising the amino acid sequence represented by SEQ ID NO: 2; (2) a protein comprising an amino acid sequence having at least 70% sequence identity with the amino acid sequence represented by SEQ ID NO: 2 and having an activity for converting PF1378B into PF1378A, (3) a protein encoded by the base sequence represented by SEQ ID NO: 1; and (4) a protein encoded by a base sequence having at least 70% sequence identity with the base sequence represented by SEQ ID NO: 1 and having an activity for converting PF1378B into PF1378A.
Need to check novelty before this filing date? Find Prior Art

Description

Method for producing PF1378A, protein, nucleic acid and transformant

[0001] The present invention relates to a method for producing PF1378A. More specifically, the present invention relates to a method for producing PF1378A, a protein, a nucleic acid, and a transformant. This application claims priority based on Japanese Patent Application No. 2023-084745, filed in Japan on May 23, 2023, the contents of which are incorporated herein by reference.

[0002] PF1378A (16-ketoaspergillimide, CAS number: 199784-50-4) is a compound represented by the following formula (1):

[0003]

[0004] PF1378A has been reported as a metabolite produced by filamentous fungi of the genus Aspergillus, and is known as a substance with anthelmintic activity against third-instar larvae of Haemonchus contortus, a mammalian gastrointestinal parasitic nematode (see, for example, Non-Patent Document 1). Patent Documents 1 and 2 describe that PF1378A exhibits insecticidal activity against agricultural pests such as the brown planthopper. Patent Document 3 describes that PF1378A exhibits insecticidal activity against animal-parasitic pests such as ticks and fleas, and is safe for mammals. No technology for producing PF1378A by liquid culture has been known to date.

[0005] International Publication No. WO 2008 / 156165 International Publication No. WO 2010 / 071218 International Publication No. WO 2010 / 071219

[0006] Banks RM, et al., Novel anthelmintic metabolites from an Aspergillus species; the aspergillimides, The Journal of Antibiotics, 50 (10), 840-846, 1997.

[0007] As described above, PF1378A is a useful compound, but it is difficult to synthesize chemically and must be biosynthesized by microbial culture or the like. Therefore, it is important to elucidate the biosynthetic pathway of PF1378A and apply it to the production of PF1378A. An object of the present invention is to provide a technology for producing PF1378A.

[0008] The inventors have discovered that in the final reaction of PF1378A biosynthesis by filamentous fungi of the genus Aspergillus, a protein encoded by the g5141 gene converts PF1378B (asperparalin A, CAS number: 195966-93-9) to PF1378A, and have completed the present invention. The g5141 gene and the protein encoded by the g5141 gene are novel genes and novel proteins discovered by the inventors. PF1378B is a compound represented by the following formula (2):

[0009]

[0010] The inventors further found that in the biosynthesis of PF1378B by filamentous fungi of the genus Aspergillus, the protein encoded by the g5151a gene converts PF1378C (asperparalin B, CAS number: 227598-73-4) to PF1378B. The g5151a gene and the protein encoded by the g5151a gene are novel gene and novel protein discovered by the inventors. PF1378C is a compound represented by the following formula (3):

[0011]

[0012] The present invention includes the following aspects: [1] A method for producing PF1378A, comprising the step (a) of contacting PF1378B with one or more proteins selected from the group consisting of the following (1) to (4) to obtain PF1378A: (1) a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2, (2) a protein consisting of an amino acid sequence having 70% or more sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 and having activity to convert PF1378B to PF1378A, (3) a protein encoded by the nucleotide sequence set forth in SEQ ID NO: 1, or (4) a protein encoded by a nucleotide sequence having 70% or more sequence identity to the nucleotide sequence set forth in SEQ ID NO: 1 and having activity to convert PF1378B to PF1378A [2] The production method according to [1], wherein the step (a) is carried out within the cells of a microorganism. [3] The production method according to [1] or [2], further comprising, before the step (a), a step (b) of contacting PF1378C with one or more proteins selected from the group consisting of the following (5) to (8) to obtain PF1378B: (5) a protein consisting of the amino acid sequence set forth in SEQ ID NO: 7, (6) a protein consisting of an amino acid sequence having 70% or more sequence identity to the amino acid sequence set forth in SEQ ID NO: 7 and having activity to convert PF1378C to PF1378B, (7) a protein encoded by the nucleotide sequence set forth in SEQ ID NO: 6, or (8) a protein encoded by a nucleotide sequence having 70% or more sequence identity to the nucleotide sequence set forth in SEQ ID NO: 6 and having activity to convert PF1378C to PF1378B. [4] The production method according to [3], wherein the step (b) is carried out within the cells of a microorganism. [5] A protein consisting of the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence having 70% or more sequence identity to the amino acid sequence set forth in SEQ ID NO: 2, and having the activity of converting PF1378B to PF1378A. [6] A protein consisting of the amino acid sequence set forth in SEQ ID NO: 7 or an amino acid sequence having 70% or more sequence identity to the amino acid sequence set forth in SEQ ID NO: 7, and having the activity of converting PF1378C to PF1378B. [7] A nucleic acid encoding the protein set forth in [5].[8] The nucleic acid according to [7], which consists of the nucleotide sequence set forth in SEQ ID NO: 1 or a nucleotide sequence having 70% or more sequence identity to the nucleotide sequence set forth in SEQ ID NO: 1, and encodes a protein having the activity of converting PF1378B to PF1378A. [9] A nucleic acid encoding the protein set forth in [6].

[10] The nucleic acid according to [9], which consists of the nucleotide sequence set forth in SEQ ID NO: 6 or a nucleotide sequence having 70% or more sequence identity to the nucleotide sequence set forth in SEQ ID NO: 6, and encodes a protein having the activity of converting PF1378C to PF1378B.

[11] A transformant into which the nucleic acid set forth in [7] or [8] has been introduced.

[12] A transformant into which the nucleic acid set forth in [9] or

[10] has been introduced.

[0013] The present invention can also be said to include the following aspects: [P1] A method for producing PF1378A, comprising the step of contacting PF1378B with a protein encoded by the g5141 gene or a mutant gene thereof to obtain PF1378A, wherein the cDNA of the g5141 gene has the nucleotide sequence set forth in SEQ ID NO: 1, the cDNA of the mutant gene of the g5141 gene has a nucleotide sequence having 70% or more sequence identity to the nucleotide sequence set forth in SEQ ID NO: 1, and the protein encoded by the mutant gene of the g5141 gene has the activity of converting PF1378B to PF1378A. [P2] The production method according to [P1], wherein the step is carried out within the cells of a microorganism. [P3] A nucleic acid encoding the g5141 gene or a mutant gene thereof, wherein the cDNA of the g5141 gene has the nucleotide sequence set forth in SEQ ID NO: 1, the cDNA of the mutant gene has a nucleotide sequence having 70% or more sequence identity to the nucleotide sequence set forth in SEQ ID NO: 1, and the protein encoded by the mutant gene has the activity of converting PF1378B to PF1378A. [P4] A transformant into which the nucleic acid set forth in [P3] has been introduced.

[0014] According to the present invention, a manufacturing technique for PF1378A can be provided.

[0015] [Method for Producing PF1378A] In one embodiment, the present invention provides a method for producing PF1378A, comprising the step (a) of contacting PF1378B with one or more proteins selected from the group consisting of the following (1) to (4) to obtain PF1378A: (1) a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2, (2) a protein consisting of an amino acid sequence having 70% or more sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 and having the activity of converting PF1378B to PF1378A, (3) a protein encoded by the nucleotide sequence set forth in SEQ ID NO: 1, (4) a protein encoded by a nucleotide sequence having 70% or more sequence identity to the nucleotide sequence set forth in SEQ ID NO: 1 and having the activity of converting PF1378B to PF1378A.

[0016] In one aspect, the production method of this embodiment includes step (a) of contacting PF1378B with a protein encoded by the g5141 gene or a mutant gene thereof to obtain PF1378A, wherein the cDNA of the g5141 gene has the base sequence set forth in SEQ ID NO: 1, the cDNA of the mutant gene has a base sequence that has 70% or more sequence identity to the base sequence set forth in SEQ ID NO: 1, and the protein encoded by the mutant gene has the activity of converting PF1378B to PF1378A.

[0017] As described later in the Examples, the inventors have demonstrated that in the final reaction of PF1378A biosynthesis in Aspergillus aculeatinus strain PF1378 (hereinafter sometimes referred to as "A. aculeatinus PF1378"), the protein encoded by the g5141 gene converts PF1378B to PF1378A. Therefore, PF1378A can be produced by contacting PF1378B with a protein encoded by the g5141 gene or a mutant gene thereof. The nucleotide sequence of the cDNA of the g5141 gene derived from A. aculeatinus PF1378 is shown in SEQ ID NO: 1. The amino acid sequence of the protein encoded by the g5141 gene is shown in SEQ ID NO: 2. The nucleotide sequence of the genomic DNA of the g5141 gene is shown in SEQ ID NO: 3.

[0018] In the production method of this embodiment, the protein consisting of the amino acid sequence set forth in SEQ ID NO: 2 may contain a mutation as long as it can convert PF1378B to PF1378A. Examples of mutations include deletion, insertion, substitution, and addition of one or several amino acids. Here, "one or several" refers to 1 to 150, 1 to 100, 1 to 50, 1 to 30, 1 to 20, 1 to 10, 1 to 5, or 1 to 3 amino acids.

[0019] Examples of mutant proteins of the amino acid sequence set forth in SEQ ID NO: 2 include those consisting of an amino acid sequence having 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity to the amino acid sequence set forth in SEQ ID NO: 2, and having the activity of converting PF1378B to PF1378A.

[0020] The sequence identity of amino acid sequences can be calculated by methods well known to those skilled in the art, for example, using Blastp (protein-protein BLAST), a search program of the BLAST (Basic Local Alignment Search Tool).

[0021] Alternatively, the sequence identity of a subject amino acid sequence to a reference amino acid sequence can be determined, for example, as follows: First, the reference amino acid sequence and the subject amino acid sequence are aligned. Here, gaps may be included in each amino acid sequence to maximize sequence identity. Next, the number of matching amino acids in the reference amino acid sequence and the subject amino acid sequence is calculated, and the sequence identity can be determined according to the following formula (F2): Sequence identity (%) = number of matching amino acids / total number of amino acids in the subject amino acid sequence × 100 (F2)

[0022] The g5141 gene may contain a mutation as long as it is capable of converting PF1378B to PF1378A. Examples of mutations include deletion, insertion, substitution, and addition of one or several bases. Here, "one or several" refers to 1 to 500, 1 to 400, 1 to 300, 1 to 200, 1 to 100, 1 to 50, 1 to 30, 1 to 20, 1 to 10, 1 to 5, or 1 to 3. Examples of mutant g5141 genes include those in which the cDNA nucleotide sequence of the mutant gene has 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity to the nucleotide sequence set forth in SEQ ID NO: 1, and the protein encoded by the mutant gene has the activity of converting PF1378B to PF1378A.

[0023] The sequence identity of nucleotide sequences can be calculated by methods well known to those skilled in the art, for example, using Blastn (nucleotide-nucleotide BLAST), a search program of the BLAST (Basic Local Alignment Search Tool).

[0024] Alternatively, the sequence identity of a subject base sequence to a reference base sequence can be determined, for example, as follows: First, the reference base sequence and the subject base sequence are aligned. Here, gaps may be included in each base sequence to maximize sequence identity. Next, the number of matching bases in the reference base sequence and the subject base sequence is calculated, and the sequence identity can be determined according to the following formula (F1): Sequence identity (%) = number of matching bases / total number of bases in the subject base sequence × 100 (F1)

[0025] The sequence identity of the mutant g5141 gene to the g5141 gene may be low in regions other than the region encoding the active domain, which refers to a domain in the protein encoded by the g5141 gene that has the activity of converting PF1378B to PF1378A.

[0026] Comparison of the amino acid sequences of the g5141 gene and its homologs indicated that the regions of positions 295 to 408, 504 to 707, 1341 to 1637, 1344 to 1502, and 1639 to 1779 in the nucleotide sequence of the genomic DNA of the g5141 gene set forth in SEQ ID NO: 3 are well conserved. This suggests that the regions of positions 295 to 408, 504 to 707, 1341 to 1637, 1344 to 1502, and 1639 to 1779 in the nucleotide sequence set forth in SEQ ID NO: 3 are important for the activity of the protein encoded by the g5141 gene. Therefore, the sequence identity of the mutant g5141 gene to the g5141 gene is preferably 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more in the regions corresponding to bases 295 to 408, 504 to 707, 1341 to 1637, 1344 to 1502, and 1639 to 1779 in SEQ ID NO: 3.

[0027] Furthermore, in a mutant gene of the g5141 gene, regions other than those corresponding to bases 295 to 408, 504 to 707, 1341 to 1637, 1344 to 1502, and 1639 to 1779 in SEQ ID NO: 3 may have less than 90% sequence identity to the g5141 gene. In this case, the lower limit of sequence identity may be, for example, 50% or more, 60% or more, 70% or more, 75% or more, 80% or more, or 85% or more.

[0028] The mutant g5141 gene may be a homolog of the g5141 gene in an organism other than A. aculeatinus PF1378, or may be a g5141 gene or its homolog artificially modified by genetic recombination technology. As used herein, a gene having a similar nucleotide sequence or a protein having a similar amino acid sequence is referred to as a homolog.

[0029] As described later in the Examples, the inventors further demonstrated that in the biosynthesis of PF1378B by Aspergillus aculeatinus strain PF1378 (hereinafter sometimes referred to as "A. aculeatinus PF1378"), the protein encoded by the g5151a gene converts PF1378C to PF1378B. Therefore, PF1378B can be produced by contacting PF1378C with a protein encoded by the g5151a gene or a mutant gene thereof. The nucleotide sequence of the cDNA of the g5151a gene derived from A. aculeatinus PF1378 is shown in SEQ ID NO:6. The amino acid sequence of the protein encoded by the g5151a gene is shown in SEQ ID NO:7. The nucleotide sequence of the genomic DNA of the g5151a gene is shown in SEQ ID NO:8.

[0030] Therefore, the production method of this embodiment may further include, before the step (a), a step (b) of contacting PF1378C with one or more proteins selected from the group consisting of the following (5) to (8) to obtain PF1378B: (5) a protein consisting of the amino acid sequence set forth in SEQ ID NO: 7, (6) a protein consisting of an amino acid sequence having 70% or more sequence identity to the amino acid sequence set forth in SEQ ID NO: 7 and having the activity of converting PF1378C to PF1378B, (7) a protein encoded by the nucleotide sequence set forth in SEQ ID NO: 6, (8) a protein encoded by a nucleotide sequence having 70% or more sequence identity to the nucleotide sequence set forth in SEQ ID NO: 6 and having the activity of converting PF1378C to PF1378B.

[0031] In one aspect, the production method of this embodiment may further include, before step (a), step (b) of contacting PF1378C with a protein encoded by the g5151a gene or a mutant gene thereof to obtain PF1378B, wherein the cDNA of the g5151a gene has the base sequence set forth in SEQ ID NO: 6, the cDNA of the mutant gene of the g5151a gene has a base sequence that has 70% or more sequence identity to the base sequence set forth in SEQ ID NO: 1, and the protein encoded by the mutant gene of the g5151a gene has the activity of converting PF1378C to PF1378B.

[0032] In the production method of this embodiment, the protein consisting of the amino acid sequence set forth in SEQ ID NO: 7 may contain a mutation, as long as PF1378C can be converted to PF1378B. Examples of mutations include deletion, insertion, substitution, and addition of one or several amino acids. Here, "one or several" refers to 1 to 100, 1 to 50, 1 to 30, 1 to 20, 1 to 10, 1 to 5, or 1 to 3 amino acids.

[0033] Examples of mutant proteins of the amino acid sequence set forth in SEQ ID NO: 7 include those having an amino acid sequence with 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity to the amino acid sequence set forth in SEQ ID NO: 7, and having the activity of converting PF1378C to PF1378B. The sequence identity is the same as that described above.

[0034] Similarly, the g5151a gene may contain a mutation, as long as it is capable of converting PF1378C to PF1378B. Examples of mutations include deletion, insertion, substitution, and addition of one or several bases. Here, "one or several" refers to 1 to 300, 1 to 200, 1 to 100, 1 to 50, 1 to 30, 1 to 20, 1 to 10, 1 to 5, or 1 to 3. Examples of mutant g5151a genes include those in which the cDNA nucleotide sequence of the mutant gene has 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity to the nucleotide sequence set forth in SEQ ID NO: 6, and the protein encoded by the mutant gene has the activity of converting PF1378C to PF1378B. The sequence identity is the same as described above.

[0035] In the production method of this embodiment, PF1378B or PF1378C may be a natural product produced by a microorganism or may be chemically synthesized. Furthermore, PF1378B or PF1378C may be unpurified or purified. Purification of PF1378B or PF1378C can be carried out using conventional separation methods that utilize their properties, such as solvent extraction, ion exchange resin methods, adsorption column chromatography, partition column chromatography, gel filtration, dialysis, precipitation, and crystallization, either alone or in appropriate combinations.

[0036] In the production method of this embodiment, the protein encoded by the g5141 gene, the g5151a gene, or a mutant gene thereof may be purified. Protein purification can be performed by affinity chromatography, hydrophobic interaction chromatography, ion exchange chromatography, gel filtration chromatography, reverse phase chromatography, etc., either alone or in appropriate combinations. Alternatively, the protein encoded by the g5141 gene, the g5151a gene, or a mutant gene thereof may contain a tag, and affinity chromatography using the tag may be performed. Known tags can be used as the tag, and examples include His tag, FLAG tag, MYC tag, HA tag, and V5 tag.

[0037] Step (a) of contacting PF1378B with a protein encoded by the g5141 gene or a mutant gene thereof to obtain PF1378A may be carried out in an appropriate reaction solution. Examples of the reaction solution include a buffer solution adjusted to an appropriate pH and salt concentration. PF1378A can be obtained by contacting PF1378B with a protein encoded by the g5141 gene or a mutant gene thereof in the above-mentioned reaction solution.

[0038] The pH of the reaction solution may be 4.0 to 9.0. The concentration of PF1378B in the reaction solution may be 30 μM to 100 mM. The concentration of the protein encoded by the g5141 gene or its mutant gene may be 3 nM to 100 μM. The reaction may be carried out at 15 to 50° C. The reaction time may be, for example, 0.5 to 400 hours.

[0039] Furthermore, step (b) of contacting PF1378C with a protein encoded by the g5151a gene or a mutant gene thereof to obtain PF1378B may be carried out in an appropriate reaction solution. Examples of the reaction solution include a buffer solution adjusted to an appropriate pH and salt concentration. PF1378B can be obtained by contacting PF1378C with a protein encoded by the g5151a gene or a mutant gene thereof in the above-mentioned reaction solution.

[0040] The pH of the reaction solution may be 4.0 to 9.0. The concentration of PF1378C in the reaction solution may be 30 μM to 100 mM. The concentration of the protein encoded by the g5151a gene or its mutant gene may be 3 nM to 100 μM. The reaction may be carried out at 15 to 50° C. The reaction time may be, for example, 0.5 to 400 hours.

[0041] In the production method of this embodiment, the step (a) of contacting PF1378B with a protein encoded by the g5141 gene or a mutant gene thereof to obtain PF1378A may be carried out within the cells of a microorganism.

[0042] In this case, PF1378B may be biosynthesized within the cells of a microorganism, and the biosynthesis of PF1378B and its conversion to PF1378A may be carried out consecutively within the cells of the same microorganism.

[0043] Furthermore, the step (b) of contacting PF1378C with a protein encoded by the g5151a gene or a mutant gene thereof to obtain PF1378B may be carried out within the cells of a microorganism.

[0044] In this case, PF1378C may be biosynthesized within the cells of a microorganism. Then, the biosynthesis of PF1378C and its conversion to PF1378B may be carried out consecutively within the cells of the same microorganism. Furthermore, the conversion of PF1378B to PF1378A may be carried out consecutively within the cells of the same microorganism.

[0045] The microorganism may be A. aculeatinus PF 1378 or a microorganism other than A. aculeatinus PF 1378. Examples of the microorganism include actinomycetes, Escherichia coli, Bacillus subtilis, yeast, and filamentous fungi.

[0046] In this case, by culturing the microorganism, PF1378B is synthesized in the microbial cells and converted to PF1378A, or PF1378C is synthesized in the microbial cells and converted to PF1378B, which is then further converted to PF1378A.

[0047] The culture conditions for the microorganisms may be appropriately selected depending on the microorganisms used. Specific culture methods include solid culture under aerobic conditions, shaking culture in a liquid medium, aeration and agitation culture, and submerged aerobic culture. A suitable temperature for culture is 15 to 40°C. Although it depends on the microorganisms used, maximum accumulation of PF1378A usually occurs within 2 to 10 days under any culture conditions. Plant cells may be used instead of the microorganisms.

[0048] The production method of this embodiment can provide a composition containing PF1378A and PF1378B, or a composition containing PF1378A, PF1378B, and PF1378C. As will be described later in the Examples, in the presence of a protein encoded by the g5151a gene or a mutant gene thereof, PF1378C is converted to PF1378B and may become barely detectable.

[0049] The resulting PF1378A can be purified by the same method as for PF1378B or PF1378C described above, for example, solvent extraction, ion exchange resin, adsorption column chromatography, partition column chromatography, gel filtration, dialysis, precipitation, crystallization, etc., either alone or in combination.

[0050] [Protein] In one embodiment, the present invention provides a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2. The protein consisting of the amino acid sequence set forth in SEQ ID NO: 2 is a novel protein discovered by the inventors. As described above, PF1378A can be produced from PF1378B using the protein of this embodiment.

[0051] The protein of this embodiment may be a non-naturally occurring protein, and may have a peptide tag for purification added to the N-terminus or C-terminus. The peptide tag is not particularly limited, and examples thereof include a histidine tag, a FLAG tag, and a MYC tag.

[0052] In one embodiment, the present invention provides a mutant protein consisting of an amino acid sequence having 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity to the amino acid sequence set forth in SEQ ID NO: 2, and having the activity of converting PF1378B to PF1378A. As described above, PF1378A can be produced from PF1378B using the protein of this embodiment.

[0053] In one embodiment, the present invention provides a protein consisting of the amino acid sequence set forth in SEQ ID NO: 7. The protein consisting of the amino acid sequence set forth in SEQ ID NO: 7 is a novel protein discovered by the inventors. As described above, PF1378B can be produced from PF1378C using the protein of this embodiment.

[0054] The protein of this embodiment may be a non-naturally occurring protein, and may have a peptide tag added to the N-terminus or C-terminus for purification. The peptide tag is the same as that described above.

[0055] In one embodiment, the present invention provides a mutant protein consisting of an amino acid sequence having 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity to the amino acid sequence set forth in SEQ ID NO: 7, and having the activity of converting PF1378C to PF1378B. As described above, PF1378B can be produced from PF1378C using the protein of this embodiment.

[0056] [Nucleic Acid] (Nucleic Acid Encoding the g5141 Gene or a Mutant Gene Thereof) In one embodiment, the present invention provides a nucleic acid encoding the g5141 gene or a mutant gene thereof, wherein the cDNA of the g5141 gene has the nucleotide sequence set forth in SEQ ID NO: 1, the cDNA of the mutant gene has a nucleotide sequence that has 70% or more sequence identity to the nucleotide sequence set forth in SEQ ID NO: 1, and the protein encoded by the mutant gene has the activity of converting PF1378B to PF1378A. The nucleic acid of this embodiment may be a non-naturally occurring nucleic acid.

[0057] In the nucleic acid of this embodiment, the g5141 gene and its mutant gene are the same as those described above. The mutant gene may have a nucleotide sequence that has 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity to the nucleotide sequence set forth in SEQ ID NO: 1, and the protein encoded by the mutant gene may have the activity of converting PF1378B to PF1378A.

[0058] The nucleic acid of this embodiment may be in the form of a nucleic acid fragment or a vector. That is, the nucleic acid of this embodiment may be a vector containing a nucleic acid encoding the g5141 gene or a mutant gene thereof. The vector may be a virus, a plasmid, a fosmid, or a cosmid. More specifically, for example, when the host is Escherichia coli, the vector may be a λ phage-based bacteriophage or a pBR or pUC-based plasmid. When the host is Bacillus subtilis, the vector may be a pUB-based plasmid. When the host is yeast, the vector may be a YEp, YRp, YCp, or YIp-based plasmid.

[0059] The nucleic acid of this embodiment preferably contains a selection marker for selecting a transformant. Examples of selection markers include drug resistance genes and genes that complement auxotrophy. More specific selection markers include ampicillin resistance genes, kanamycin resistance genes, and tetracycline resistance genes when the host is a bacterium. Furthermore, examples of selection markers include tryptophan biosynthesis genes (TRP1), uracil biosynthesis genes (URA3), and leucine biosynthesis genes (LEU2) when the host is a yeast. Furthermore, examples of selection markers include hygromycin resistance genes, bialaphos resistance genes, bleomycin resistance genes, aureobasidin resistance genes, pyrithiamine resistance genes, and oligomycin resistance genes when the host is a filamentous fungus. Furthermore, examples of selection markers include kanamycin resistance genes and bialaphos resistance genes when the host is a plant.

[0060] The nucleic acid may have transcriptional or translational regulatory signals necessary for gene expression, such as a promoter, a transcription initiation signal, a ribosome binding site, a translation stop signal, or a transcription termination signal.

[0061] Examples of promoters include lactose operon promoters and tryptophan operon promoters when the host is Escherichia coli. Furthermore, examples of promoters include alcohol dehydrogenase gene promoters, acid phosphatase gene promoters, galactose assimilation gene promoters, and glyceraldehyde-3-phosphate dehydrogenase promoters when the host is yeast. Furthermore, examples of promoters include α-amylase gene promoters, glucoamylase gene promoters, translation elongation factor 1-α gene promoters, and enolase gene promoters when the host is a filamentous fungus. Furthermore, examples of promoters include CaMV 35S RNA promoters, CaMV 19S RNA promoters, and nopaline synthase gene promoters when the host is a plant.

[0062] (Nucleic acid encoding the g5151a gene or a mutant gene thereof) In one embodiment, the present invention provides a nucleic acid encoding the g5151a gene or a mutant gene thereof, wherein the cDNA of the g5151a gene has the nucleotide sequence set forth in SEQ ID NO: 6, the cDNA of the mutant gene has a nucleotide sequence that has 70% or more sequence identity to the nucleotide sequence set forth in SEQ ID NO: 6, and the protein encoded by the mutant gene has the activity of converting PF1378C to PF1378B. The nucleic acid of this embodiment may be a non-naturally occurring nucleic acid.

[0063] In the nucleic acid of this embodiment, the g5151a gene and its mutant gene are the same as those described above. The mutant gene may have a nucleotide sequence that has 70% or more, 80% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity to the nucleotide sequence set forth in SEQ ID NO: 6, and the protein encoded by the mutant gene may have the activity of converting PF1378C to PF1378B.

[0064] The nucleic acid of this embodiment may be in the form of a nucleic acid fragment or a vector. That is, the nucleic acid of this embodiment may be a vector containing a nucleic acid encoding the g5151a gene or a mutant gene thereof. The vector is the same as that described above.

[0065] The nucleic acid of this embodiment preferably contains a selection marker for selecting a transformant, which is the same as that described above.

[0066] The nucleic acid may have transcriptional and translational regulatory signals necessary for gene expression, which are the same as those described above.

[0067] [Transformant] (Transformant into which a nucleic acid encoding the g5141 gene or a mutant gene thereof has been introduced) In one embodiment, the present invention provides a transformant into which a nucleic acid encoding the g5141 gene or a mutant gene thereof has been introduced. The transformant of this embodiment may be obtained by introducing a nucleic acid fragment into a host using a homologous recombination technique, or by introducing a vector into a host. Examples of hosts include actinomycetes, Escherichia coli, Bacillus subtilis, yeast, filamentous fungi, and plants. The nucleic acid is the same as that described above, and an appropriate one may be selected appropriately depending on the host.

[0068] The method for introducing nucleic acid into a host may be appropriately selected depending on the form of the nucleic acid and the host, and examples include conjugative transfer, phage-mediated transduction, calcium ion method, lithium ion method, electroporation method, PEG method, Agrobacterium method, particle gun method, etc.

[0069] The transformant of this embodiment can be used, for example, as a storage medium (carrier) for the g5141 gene or a mutant gene thereof.

[0070] Alternatively, a protein encoded by the g5141 gene or a mutant gene thereof can be expressed in the cells of the transformant of this embodiment, and therefore the transformant of this embodiment can be used to convert PF1378B to PF1378A.

[0071] Furthermore, when the transformant of this embodiment is capable of biosynthesizing PF1378B, the transformant of this embodiment can be cultured to carry out biosynthesis of PF1378B and conversion to PF1378A, thereby producing PF1378A. The method for culturing the transformant and the purification of the resulting PF1378A are the same as those described above.

[0072] (Transformant into which a nucleic acid encoding the g5151a gene or a mutant gene thereof has been introduced) In one embodiment, the present invention provides a transformant into which a nucleic acid encoding the above-mentioned g5151a gene or a mutant gene thereof has been introduced. The transformant of this embodiment may be obtained by introducing a nucleic acid fragment into a host using a homologous recombination technique, or by introducing a vector into a host. The host and the method for introducing the nucleic acid into the host are the same as those described above.

[0073] The transformant of this embodiment can be used, for example, as a storage medium (carrier) for the g5151a gene or a mutant gene thereof.

[0074] Alternatively, a protein encoded by the g5151a gene or a mutant gene thereof can be expressed in the cells of the transformant of this embodiment, and therefore the transformant of this embodiment can be used to convert PF1378C to PF1378B.

[0075] Furthermore, when the transformant of this embodiment is capable of biosynthesizing PF1378C, the biosynthesis of PF1378C and its conversion to PF1378B can be achieved by culturing the transformant of this embodiment.

[0076] Furthermore, when the transformant of this embodiment is further transformed with a nucleic acid encoding the g5141 gene or a mutant gene thereof, PF1378B can be converted to PF1378A to produce PF1378A. The method for culturing the transformant and the purification of the resulting PF1378A are the same as those described above.

[0077] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to the following examples.

[0078] Experimental Example 1 (Creation of a Strain of A. aculeatinus PF1378 Deficient in Nonhomologous End Joining Function) The entire genome of A. aculeatinus PF1378 was analyzed. From the whole genome analysis data, the presence of a homologue (g6418) of ku70, which is known to be involved in nonhomologous end joining in Aspergillus oryzae, was confirmed. The nucleotide sequence of g6418 is shown in SEQ ID NO: 4. Therefore, a g6418 knockout strain was created by inserting a hygromycin resistance gene into g6418.

[0079] A gene fragment containing, in this order, the 5' upstream partial fragment of g6418, an expression construct for a hygromycin resistance gene, and the 3' downstream partial fragment of g6418 was prepared. The resulting gene fragment was then introduced into A. aculeatinus PF1378 by the protoplast-PEG method. The cells were then cultured on Czapek-Dox agar medium containing 25 μg / mL hygromycin, and the desired transformants were selected. The resulting transformant in which the ku70 homolog was disrupted was designated A. aculeatinus PF1378 Δku70.

[0080] Experimental Example 2 (Creation of uracil-requiring A. aculeatinus PF1378 Δku70) From the whole genome analysis data of A. aculeatinus PF1378, the presence of a homolog (g3123) of the pyrG enzyme gene that constitutes the uracil biosynthetic pathway of A. oryzae was confirmed. The nucleotide sequence of g3123 is shown in SEQ ID NO: 5. Therefore, the pyrithiamine resistance gene of A. oryzae was inserted into g3123 as a selection marker to create uracil-requiring A. aculeatinus PF1378 Δku70.

[0081] A gene fragment containing, in this order, the 5' upstream fragment of g3123, an expression construct for the pyrithiamine resistance gene, and the 3' downstream fragment of g3123 was prepared. The resulting gene fragment was then introduced into A. aculeatinus PF1378 Δku70 by the protoplast-PEG method. The desired transformants were then selected on Czapek-Dox agar medium containing 1 μg / mL pyrithiamine hydrobromide, 5 mM uridine, and 10 mM uracil. The resulting pyrithiamine-resistant transformant, i.e., the uracil-requiring transformant, was designated A. aculeatinus PF1378 Δku70 ΔpyrG.

[0082] Experimental Example 3 (Introduction of Cre / loxP marker recycling system into A. aculeatinus PF1378 Δku70 ΔpyrG) The Cre / loxP marker recycling system using the pyrG gene derived from A. oryzae as a selection marker was introduced into the pyrithiamine resistance gene site of A. aculeatinus PF1378 Δku70 ΔpyrG obtained in Experimental Example 2.

[0083] A gene fragment containing, in this order, the 5' upstream partial fragment of g3123, lox66 sequence, A. oryzae-derived pyrG gene, lox71 sequence, A. oryzae-derived xylanase gene promoter region, Cre coding region, A. oryzae-derived α-glucosidase gene terminator region, and the 3' downstream partial fragment of g3123 was prepared. Subsequently, the resulting gene fragment was introduced into A. aculeatinus PF1378 Δku70 ΔpyrG by the protoplast-PEG method. Subsequently, the desired transformants were selected on Czapek-Dox agar medium.

[0084] The resulting strain in which the pyrithiamine resistance gene of A. aculeatinus PF1378 Δku70 ΔpyrG had been replaced with the A. oryzae-derived pyrG gene and the Cre / loxP marker recycling gene cassette was designated A. aculeatinus PF1378 Δku70 Cre.

[0085] Experimental Example 4 (Removal of the A. oryzae-derived pyrG gene from A. aculeatinus PF1378 Δku70 Cre) The A. aculeatinus PF1378 Δku70 Cre prepared in Experimental Example 3 was cultured in Czapek-Dox medium containing 5 mM uridine, 10 mM uracil, and 1 mg / mL 5-fluoroorotic acid, with 2% xylose as a carbon source, and the Cre / loxP marker recycling system was induced to select a strain in which the A. oryzae-derived pyrG gene had been removed. The resulting strain in which the A. oryzae-derived pyrG gene had been removed was designated A. aculeatinus PF1378 Δku70 Cre [pyrG-].

[0086] Experimental Example 5 (Removal of the g5141 gene from A. aculeatinus PF1378 Δku70 Cre [pyrG-]) The presence of the g5141 gene was confirmed from whole genome analysis data of A. aculeatinus PF1378. The nucleotide sequence of the cDNA of the g5141 gene is shown in SEQ ID NO: 1. The amino acid sequence of the protein encoded by the g5141 gene is shown in SEQ ID NO: 2. The nucleotide sequence of the genomic DNA of the g5141 gene is shown in SEQ ID NO: 3.

[0087] Subsequently, the g3123 gene, which is the pyrG gene of A. aculeatinus PF1378, was inserted into the g5141 locus to create a g5141 knockout strain.

[0088] A gene fragment containing, in this order, the 5' upstream partial fragment of g5141, the g3123 region of the pyrG gene of PF1378, and the 3' downstream partial fragment of g5141 was prepared. The resulting gene fragment was then introduced into A. aculeatinus PF1378 Δku70 Cre [pyrG-] by the protoplast-PEG method. The desired transformants were then selected on Czapek-Dox agar medium. The resulting g5141-deficient strain was designated A. aculeatinus PF1378 Δku70 Cre Δg5141.

[0089] Experimental Example 6 (Removal of the g5151a gene from A. aculeatinus PF1378 Δku70 Cre [pyrG-]) The presence of the g5151a gene was confirmed from whole genome analysis data of A. aculeatinus PF1378. The nucleotide sequence of the cDNA of the g5151a gene is shown in SEQ ID NO: 6. The amino acid sequence of the protein encoded by the g5151a gene is shown in SEQ ID NO: 7. The nucleotide sequence of the genomic DNA of the g5151a gene is shown in SEQ ID NO: 8.

[0090] Subsequently, the g3123 gene, which is the pyrG gene of A. aculeatinus PF1378, was inserted into the g5151a locus to create a g5151a knockout strain.

[0091] A gene fragment containing, in this order, the 5' upstream partial fragment of g5151a, the g3123 region of the pyrG gene of PF1378, and the 3' downstream partial fragment of g5151a was prepared. The resulting gene fragment was then introduced into A. aculeatinus PF1378 Δku70 Cre [pyrG-] by the protoplast-PEG method. The desired transformants were then selected on Czapek-Dox agar medium. The resulting g5151a-deficient strain was designated A. aculeatinus PF1378 Δku70 Cre Δg5151a.

[0092] Experimental Example 7 (Investigation of the ability of A. aculeatinus PF1378 Δku70 Cre Δg5141 to produce PF1378A and PF1378B) The ability of A. aculeatinus PF1378 Δku70 Cre Δg5141 to produce PF1378A and PF1378B was investigated.

[0093] A. aculeatinus PF1378 and A. aculeatinus PF1378 Δku70 Cre Δg5141 were cultured on Potato Dextrose agar medium, and conidia were collected. Subsequently, conidia suspended in a 0.01% Tween 20 aqueous solution were collected at 4 × 10 5 The solution was diluted to a concentration of conidia / mL to prepare a conidia suspension.

[0094] Brown rice (Akitakomachi) soaked overnight in water was autoclaved at 121°C for 20 minutes to prepare a rice culture medium. Five grams of the prepared rice culture medium was placed in a bioreactor tube (TPP® TubeSpin 50 mL) and inoculated with 500 μL of a conidial suspension. The inoculated rice culture medium was then statically cultured at 25°C, and after 7 days, 10 mL of 67% aqueous acetone solution was added. After the addition, the mixture was thoroughly stirred on a shaker for 1 hour and centrifuged at 4°C and 10,000 × g for 60 minutes. The resulting supernatant was used as a sample, and PF1378A and PF1378B were quantified by HPLC. The test was performed with n=5.

[0095] The quantification results for PF1378A are shown in Table 1 below, and the quantification results for PF1378B are shown in Table 2 below. As a result, production of both PF1378A and PF1378B was detected in A. aculeatinus PF1378. On the other hand, production of PF1378B was detected in A. aculeatinus PF1378 Δku70 Cre Δg5141, but production of PF1378A was not detected. This confirmed that the protein encoded by the g5141 gene is involved in the conversion of PF1378B to PF1378A. In other words, it was revealed that a transformant in which the g5141 gene was introduced into a microorganism that does not possess the g5141 gene and produces PF1378B, or a transformant in which the g5141 gene was introduced into a microorganism that can externally provide PF1378B, can produce PF1378A.

[0096]

[0097]

[0098] Experimental Example 8 (Investigation of the ability of A. aculeatinus PF1378 Δku70 Cre Δg5151a to produce PF1378A, PF1378B, and PF1378C) The ability of A. aculeatinus PF1378 Δku70 Cre Δg5151a to produce PF1378A, PF1378B, and PF1378C was investigated.

[0099] A. aculeatinus PF1378 and A. aculeatinus PF1378 Δku70 Cre Δg5151a were cultured on Potato Dextrose agar medium, and conidia were collected. Subsequently, conidia suspended in a 0.01% Tween 20 aqueous solution were collected at 4 × 10 5 The solution was diluted to a concentration of conidia / mL to prepare a conidia suspension.

[0100] Barley (marubari barley from Saga Prefecture) soaked in water for 2 hours was autoclaved at 121°C for 20 minutes to prepare a barley culture medium. Five grams of the prepared barley culture medium was placed in a bioreactor tube (TPP® TubeSpin 50 mL) and inoculated with 500 μL of a conidial suspension. The inoculated barley culture medium was then statically cultured at 25°C, and after 7 days, 10 mL of 67% aqueous acetone solution was added. After the addition, the mixture was thoroughly stirred on a shaker for 1 hour and centrifuged at 4°C and 10,000 × g for 60 minutes. The resulting supernatant was dried using a centrifugal concentrator and dissolved in an equal volume of methanol. This was used as a sample and analyzed for PF1378A, PF1378B, and PF1378C by LCMS.

[0101] The quantitative results of PF1378A, PF1378B, and PF1378C are shown in Table 3 below. In Table 3, "N.D." indicates that the results were below the detection limit. The peak area at m / z 374 was taken as the production amount of PF1378A, the peak area at m / z 360 was taken as the production amount of PF1378B, and the peak area at m / z 346 was taken as the production amount of PF1378C. The production amount of PF1378A in the A. aculeatinus PF1378 strain was taken as 100, and the production amount of PF1378B was taken as 100. The production amount of PF1378C was also shown as a relative value, with the production amount of PF1378B in the A. aculeatinus PF1378 strain taken as 100.

[0102] As a result, in A. aculeatinus PF1378, production of both PF1378A and PF1378B was detected. On the other hand, in A. aculeatinus PF1378 Δku70 Cre Δg5151a, production of PF1378C was detected, but production of PF1378A and PF1378B was not detected. From this, it was confirmed that the protein encoded by the g5151a gene is involved in the conversion of PF1378C to PF1378B. That is, it was revealed that a transformant in which the g5151a gene was introduced into a microorganism that does not possess the g5151a gene and produces PF1378C, or a transformant in which the g5151a gene was introduced into a microorganism that can externally provide PF1378C, can produce PF1378B.

[0103]

[0104] Experimental Example 9 (Removal of g5141 gene from A. aculeatinus PF1378 Δku70 Cre [pyrG-], removal of pyrG gene, and separate introduction of g5141 gene) A g5141 knockout strain was created by inserting the g3123 gene, which is the pyrG gene of A. aculeatinus PF1378, into the g5141 locus of A. aculeatinus PF1378. In this case, the strain was designed so that the pyrG gene could be removed after creation of the knockout strain. After creating the knockout strain, the pyrG gene was removed, and finally, the pyrG gene was separately introduced as a selection marker in a manner that consistently expressed g5141.

[0105] A gene fragment containing, in this order, the 5' upstream partial fragment of g5141, the lox66 sequence, the g3123 gene (the pyrG gene of PF1378), the lox71 sequence, and the 3' downstream partial fragment of g5141 was prepared. The resulting gene fragment was then introduced into A. aculeatinus PF1378 Δku70 Cre [pyrG-] by the protoplast-PEG method. The desired transformants were then selected on Czapek-Dox agar medium. The resulting strain in which the g5141 gene had been removed and the pyrG gene could be removed was named A. aculeatinus PF1378 Δku70 Cre Δg5141::lox66::pyrG::lox71.

[0106] Subsequently, A. aculeatinus PF1378 Δku70 Cre Δg5141:: lox66:: pyrG:: lox71 was cultured in Czapek-Dox medium containing 5 mM uridine, 10 mM uracil, and 1 mg / mL 5-fluoroorotic acid, with 2% xylose as a carbon source, and the Cre / loxP marker recycling system was induced to select strains in which the pyrG gene had been removed. The resulting strain in which the pyrG gene from PF1378 had been removed was named A. aculeatinus PF1378 Δku70 Cre Δg5141 [pyrG-].

[0107] Whole genome analysis data for A. aculeatinus PF1378 confirmed the presence of a homologue (g4093) of tef1, the translation elongation factor 1-α gene of A. oryzae. The nucleotide sequence of the 1,012-bp promoter of g4093 is shown in SEQ ID NO: 9. A strain was constructed by separately introducing g5141 into A. aculeatinus PF1378 Δku70 Cre Δg5141 [pyrG-] in a manner that allowed expression using the g4093 promoter. A gene fragment containing, in this order, the 5' upstream partial fragment of g5141, the g3123 gene (the pyrG gene of PF1378), the promoter region of the g4093 gene, the g5141 coding region shown in SEQ ID NO: 3, and the 3' downstream partial fragment of g5141 was prepared. The resulting gene fragment was then introduced into A. aculeatinus PF1378 Δku70 Cre Δg5141 [pyrG-] by the protoplast-PEG method. The desired transformants were then selected on Czapek-Dox agar medium. The resulting strain into which the g5141 gene was separately introduced so that it was expressed under the g4093 promoter was designated A. aculeatinus PF1378 Δku70 Cre Δg5141::pyrG::Pg4093::g5141.

[0108] [Experimental Example 10] (Investigation of the ability of A. aculeatinus PF1378 Δku70 Cre Δg5141::pyrG::Pg4093::g5141 to produce PF1378A and PF1378B) The ability of the strain prepared in Experimental Example 9, A. aculeatinus PF1378 Δku70 Cre Δg5141 [pyrG-], to produce PF1378A and PF1378B was investigated.

[0109] Barley (marubari barley from Saga Prefecture) soaked in water for 2 hours was autoclaved at 121°C for 20 minutes to prepare a barley culture medium. Five grams of the prepared barley culture medium was placed in a bioreactor tube (TPP® TubeSpin 50 mL), and 500 μL of a conidial suspension was inoculated. The barley culture medium inoculated with the conidial suspension was then statically cultured at 25°C, and after 7 days, 10 mL of 67% aqueous acetone solution was added. After the addition, the mixture was thoroughly stirred on a shaker for 1 hour and centrifuged at 4°C and 10,000 × g for 60 minutes. The resulting supernatant was used as a sample and PF1378A and PF1378B were measured by LCMS. The test was performed in duplicate.

[0110] The quantification results for PF1378A are shown in Table 4 below, and the quantification results for PF1378B are shown in Table 5 below. As a result, production of both PF1378A and PF1378B was detected in A. aculeatinus PF1378 Δku70 Cre Δg5141::pyrG::Pg4093::g5141. As shown in Example 7, A. aculeatinus PF1378 Δku70 Cre Δg5141 does not produce PF1378A, so this result further supports the idea that the protein encoded by the g5141 gene is involved in the conversion of PF1378B to PF1378A. In other words, it was further supported that a transformant in which the g5141 gene was introduced into a microorganism that does not possess the g5141 gene and produces PF1378B, or a transformant in which the g5141 gene was introduced into a microorganism that can exogenously provide PF1378B, can produce PF1378A.

[0111]

[0112]

[0113] According to the present invention, a manufacturing technique for PF1378A can be provided.

Claims

1. A method for producing PF1378A, comprising the step (a) of contacting PF1378B with one or more proteins selected from the group consisting of the following (1) to (4) to obtain PF1378A: (1) a protein consisting of the amino acid sequence set forth in SEQ ID NO: 2, (2) a protein consisting of an amino acid sequence having 70% or more sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 and having activity to convert PF1378B to PF1378A, (3) a protein encoded by the base sequence set forth in SEQ ID NO: 1, (4) a protein encoded by a base sequence having 70% or more sequence identity to the base sequence set forth in SEQ ID NO: 1 and having activity to convert PF1378B to PF1378A.

2. The method according to claim 1, wherein step (a) is carried out within a microbial cell.

3. The method according to claim 1 or 2, further comprising a step (b) of contacting PF1378C with one or more proteins selected from the group consisting of the following (5) to (8) to obtain PF1378B, prior to the step (a): (5) a protein consisting of the amino acid sequence set forth in SEQ ID NO: 7, (6) a protein consisting of an amino acid sequence having 70% or more sequence identity to the amino acid sequence set forth in SEQ ID NO: 7 and having an activity of converting PF1378C to PF1378B, (7) a protein encoded by the base sequence set forth in SEQ ID NO: 6, (8) a protein encoded by a base sequence having 70% or more sequence identity to the base sequence set forth in SEQ ID NO: 6 and having an activity of converting PF1378C to PF1378B.

4. The method according to claim 3, wherein step (b) is carried out within a microbial cell.

5. A protein consisting of the amino acid sequence set forth in SEQ ID NO: 2, or consisting of an amino acid sequence having 70% or more sequence identity to the amino acid sequence set forth in SEQ ID NO: 2, and having the activity of converting PF1378B to PF1378A.

6. A protein consisting of the amino acid sequence set forth in SEQ ID NO: 7, or consisting of an amino acid sequence having 70% or more sequence identity to the amino acid sequence set forth in SEQ ID NO: 7, and having the activity of converting PF1378C to PF1378B.

7. A nucleic acid encoding the protein of claim 5.

8. The nucleic acid according to claim 7, which consists of the base sequence set forth in SEQ ID NO: 1 or has a base sequence having 70% or more sequence identity to the base sequence set forth in SEQ ID NO: 1 and encodes a protein having an activity of converting PF1378B to PF1378A.

9. A nucleic acid encoding the protein of claim 6.

10. The nucleic acid according to claim 9, which consists of the base sequence set forth in SEQ ID NO:6 or has a base sequence having 70% or more sequence identity to the base sequence set forth in SEQ ID NO:6, and encodes a protein having the activity of converting PF1378C to PF1378B.

11. A transformant into which the nucleic acid according to claim 7 or 8 has been introduced.

12. A transformant into which the nucleic acid according to claim 9 or 10 has been introduced.

Citation Information

Patent Citations

  • Portable stove device

    JP2023084745A

  • Insecticide for agricultural / horticultural use comprising 16-ketoaspergillimide as the active ingredient

    WO2008156165A1

  • Composition to control harmful organisms that contains 16-keto aspergillimide

    WO2010071218A1

  • 16-ketoaspergillimide and pest exterminating agent comprising the same as active ingredient

    WO2010071219A1

  • Plant parasitic nematode controlling agent and plant parasitic nematode controlling method

    WO2020241702A1

Cited By

  • Pest control agent composition and method of use

    JP2026138910A